The Invisible Engineering Behind Specialty Drugs: How Pharma Hubs Become Gatekeepers of Whether Patients Can Stay on Treatment
The challenge of high-priced specialty drugs often lies not only in the laboratory or on a physician’s prescription, but in whether insurance, assistance, distribution, and follow-up can all hold together; so-called pharma hubs are turning this fragile path into core infrastructure for healthcare access.